Pharmaceuticals
Turn Biotechnologies Introduces its Dermatology Platform to the European Aesthetic Community at AMWC
MOUNTAIN VIEW, Calif., March 30, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, announced that it will for the first time share new data for its revolutionary dermatology platform with the interna...
2023-03-30 20:00
3300
ACROBiosystems' new strategic focus - streamlining the transition from preclinical development to commercialization
NEWARK, Del., March 30, 2023 /PRNewswire/ -- With more than 10 years of experience in protein development, ACROBiosystems has continuously demonstrated its strength in developing products and services throughout the entire drug development process. As such, ACROBiosystems has begun to narrow its ...
2023-03-30 18:54
1899
DxVx Co., Ltd.'s affiliated company, Oxford Vacmedix (OVM) successfully completed Phase 1a in clinical trial of novel cancer vaccine OVM-200
SEOUL, South Korea, March 30, 2023 /PRNewswire/ -- DXVX announces that its affiliated company Oxford Vacmedix (OVM) has completed Phase 1a trial of cancer vaccine and plans to proceed Phase1b trial of OVM-200. DxVx Co., Ltd. is the Korean Stock market (KOSDAQ) listed company and is the largest s...
2023-03-30 17:39
1932
Great Place To Work unveils Best Workplaces in the Inaugural Singapore Healthcare and Biopharma List 2023
Employees express trust in leaders' competence and integrity and value fairness and impartiality as part of the workplace culture SINGAPORE, March 30, 2023 /PRNewswire/ -- Great Place To Work®, the global authority on workplace culture announced the 10 companies who are Best WorkplacesTM in its ...
2023-03-30 12:00
2512
ImmVira's oncolytic product MVR-C5252 targeting malignant glioma obtained NMPA's approval for Clinical Trial in China
SHENZHEN, China, March 29, 2023 /PRNewswire/ -- ImmVira announced that its oncolytic virus product MVR-C5252 targeting malignant glioma obtained the approval from National Medical Products Administration ("NMPA") for Phase I clinical trial inChina on March 29, 2023. Previously, MVR-C5252 also obt...
2023-03-30 08:00
1752
JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 406 Patients
SHANGHAI, March 30, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that as ofMarch 29, 2023, the company has conducted 13 clinical studies cover...
2023-03-30 08:00
2778
Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063
- ATH-063 is a novel, oral, first-in-class, small molecule therapeutic targeting both inflammation and direct mucosal healing in patients with ulcerative colitis and Crohn's disease - LOS ANGELES, March 30, 2023 /PRNewswire/ -- Athos Therapeutics, Inc. ("Athos"), a clinical stage biotechnology ...
2023-03-30 03:32
2616
bitBiome and Kaken Pharmaceuticals sign joint research agreement on the discovery of drugs for infectious diseases
-The joint research will use bitBiome's drug discovery platform technology to search for drug candidate substances- TOKYO, March 29, 2023 /PRNewswire/ -- bitBiome, Inc. (Head office: Shinjuku-ku,Tokyo; President: Yuji Suzuki; hereafter 'bitBiome') and Kaken Pharmaceuticals (Head office: Bunkyo-k...
2023-03-29 22:00
2034
HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth
* Su-jin Park joins HanAll Biopharma in a shared leadership role to strengthen pharmaceutical business in Korea, supporting growth in domestic drug sales * Sean Jeong, who has been serving as Co-CEO since March 2021, will continue to lead HanAll's R&D, including its subsidiary HanAll Pharmace...
2023-03-29 19:00
1478
BGI Genomics Partners with Zentya to Launch Fecal DNA Test for Colorectal Cancer in Slovakia
BRATISLAVA, Slovakia, March 29, 2023 /PRNewswire/ -- BGI Genomics is pleased to announce the launch of COLOTECTTM 1.0 in Slovakia, in collaboration with its partner, Zentya. Zentya is a Slovak-based company that is passionate about providing patients with the latest technology in genetic screenin...
2023-03-29 16:00
1376
Fosun Pharma Announces its 15th Corporate Social Responsibility Report: Continuous Innovation for the Benefit of the Public
SHANGHAI, March 29, 2023 /PRNewswire/ -- On March 27, 2023, the release date of its 2022 Annual Report, Fosun Pharma (stock code: 600196.SH; 02196.HK) also released the2022 Corporate Social Responsibility Report, its 15th CSR report since the first which was issued in 2009. As before, Fosun Pharm...
2023-03-29 14:06
1761
Transcenta's Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer
SUZHOU, China, March 29, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces that the U.S. Food an...
2023-03-29 14:00
3181
Antengene Announces First Patient Dosed with Claudin 18.2 Antibody-Drug Conjugate ATG-022 for the Treatment of Patients with Advanced or Metastatic Solid Tumors in Australia
* Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Associated Antigen (TAA) Claudin 18.2. * The Phase I CLINCH trial is designed to evaluate the safety, pharmacology, and preliminary efficacy of ATG-022 monotherapy in p...
2023-03-29 08:30
2467
Innovent Announces 2022 Annual Results and Business Updates
Building an Innovative Biopharmaceutical Company with Sustainable Growth and Comprehensive Capability ROCKVILLE, Md. and SUZHOU, China, March 29, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commer...
2023-03-29 08:00
3336
Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China
SUZHOU, China, March 28, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the enrollment of 740 subjects recently for...
2023-03-28 21:41
1617
Antengene Announces Results for Full Year 2022 with Updates Highlighting a Sales Revenue Reaching 5.6 Times Year-Over-Year and Accelerated Global Innovation
SHANGHAI and HONG KONG, March 28, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), today announced its full-year 2022 financial results and provided updates on key events and achievements since the start of 2022. 1. Sales Revenue Reached 5.6 Times Year-Over-Year ...
2023-03-28 21:40
2518
PharmaBlock Receives 2023 ACS CMO Excellence in Green Chemistry Award
NANJING, China, March 28, 2023 /PRNewswire/ -- PharmaBlock (Stock code: 300725.SZSE), a global, fully integrated CDMO company focusing on innovative chemistry and low-carbon manufacturing, announced today that it has been selected asthe winner of the 2023 CMO Excellence in Green Chemistry Award ...
2023-03-28 20:00
1662
Sirnaomics Announces 2022 Annual Results
Significant Progress in Clinical Trials for Core Products Reinforces Leading Position in RNA Therapeutics with Strong Product Pipeline Matrix Business Highlights * Clinical development * STP705 - The part-one Phase IIb interim data on STP705 for the treatment of isSCC was announced, with th...
2023-03-28 19:26
6948
Seegene declares to share Syndromic PCR technologies to prevent future pandemics
* Localization of Seegene Syndromic PCR technologies with global partners for versatile and proactive response to local emerging healthcare demands. * Formation of a collaborative global network to aggressively develop innovative syndromic PCR assays, challenging boundaries of PCR application....
2023-03-28 19:00
1915
Grey Wolf Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GRWD5769 in Patients with Advanced Solid Tumours
First-in-Class ERAP1 Inhibitor Enters Clinical Development Study to Evaluate GRWD5769 as Monotherapy, as well as in Combination with PD-1 Inhibitor Libtayo® (cemiplimab) OXFORD, UK and MELBOURNE, AUSTRALIA, March 28, 2023 /PRNewswire/ -- Grey Wolf Therapeutics, a biotechnology company focused on...
2023-03-28 19:00
1552
Week's Top Stories
Most Reposted
Agoda releases generative AI film to capture the joy of travel
[Picked up by 349 media titles]
2024-12-10 10:00
Singapore's IMAGINE AI: Largest Global Gathering to Shape the Future of Healthcare with AI Innovations
[Picked up by 316 media titles]
2024-12-06 10:41
Mastercard Economics Institute: APAC growth expected to hold steady in 2025; global policy resets may see shift in gears
[Picked up by 313 media titles]
2024-12-10 09:00Building Asia's Future: Omni HR Secures $7.4mn for HR Tech Expansion
[Picked up by 306 media titles]
2024-12-09 10:00
CCTV+: Yuhang Journey ǀ Follow Olivier to Explore Ancient Liangzhu and Savor Jingshan Tea
[Picked up by 283 media titles]
2024-12-08 20:07Most Read
Singapore's IMAGINE AI: Largest Global Gathering to Shape the Future of Healthcare with AI Innovations
2024-12-06 10:41
7023
Qi Biodesign Completes $75 Million in Total Funding to Drive Genome Editing Innovations
2024-12-06 20:15
6576
BROOKLYN NETS AND PHOENIX SUNS TO PLAY TWO PRESEASON GAMES IN MACAO IN OCTOBER 2025
2024-12-06 21:09
5815
